TG4050
Head and Neck Cancer (Adjuvant)
Key Facts
About Transgene
Transgene is a clinical-stage biotech focused on reshaping early-stage cancer treatment through its individualized neoantigen therapeutic vaccine (INTV) platform, myvac®. The company's lead asset, TG4050, is in Phase I/II trials for head and neck cancer, with promising early data suggesting potential to prevent relapse post-surgery. Under the leadership of industry veteran Alessandro Riva, Transgene has strategically pivoted to this high-potential niche, backed by financial visibility into early 2028, positioning it to advance a potentially transformative immunotherapy paradigm.
View full company profileAbout Transgene
Transgene is a clinical-stage biotech focused on reshaping early-stage cancer treatment through its individualized neoantigen therapeutic vaccine (INTV) platform, myvac®. The company's lead asset, TG4050, is in Phase I/II trials for head and neck cancer, with promising early data suggesting potential to prevent relapse post-surgery. Under the leadership of industry veteran Alessandro Riva, Transgene has strategically pivoted to this high-potential niche, backed by financial visibility into early 2028, positioning it to advance a potentially transformative immunotherapy paradigm.
View full company profileAbout transgene-sa
Transgene SA is a clinical-stage biotech focused on developing Individualized Neoantigen Therapeutic Vaccines (INTV) for early-stage solid tumors. The company's core asset is the myvac® platform, a viral vector system designed to elicit potent, tumor-specific T-cell responses. Under CEO Alessandro Riva, Transgene has undergone a strategic refocusing, prioritizing its lead program TG4050 in head and neck cancer, supported by a cash runway into early 2028. Recent Phase I data, presented as a preprint, suggests potential in preventing cancer relapse.
View full company profileAbout transgene-sa
Transgene SA is a clinical-stage biotech focused on developing Individualized Neoantigen Therapeutic Vaccines (INTV) for early-stage solid tumors. The company's core asset is the myvac® platform, a viral vector system designed to elicit potent, tumor-specific T-cell responses. Under CEO Alessandro Riva, Transgene has undergone a strategic refocusing, prioritizing its lead program TG4050 in head and neck cancer, supported by a cash runway into early 2028. Recent Phase I data, presented as a preprint, suggests potential in preventing cancer relapse.
View full company profile